Abstract
Abstract: The aim of this study is to evaluate the clinical
characteristics and outcomes in 2019 novel coronavirus patients and to
help clinicians perform correct treatment and evaluate prognosis and
guide the treatment. Methods: 239 patients who were diagnosed with
COVID-19 were included in this study. Patients were divided into the
improvement group and the death group according to their outcome
(improvement or death).Clinical characteristics and laboratory
parameters were collected from medical records. Continuous variables
were tested by independent sample T test, and categorical variables were
analyzed by chi-square test or Fisher exact test. Cox proportional
hazard regression model was used for survival analysis in death
patients. Results: Efficacy evaluation indicated that 99 patients
(41.4%) had deteriorated, and 140 patients (58.6%) had improved.
Oxygen saturation, hemoglobin levels, infection-related indicators,
lymphocyte and platelets counts, C-reactive protein, serum albumin,
liver and kidney function and lactate dehydrogenase in improvement group
were statistically significant between the improvement and death groups.
Survival analysis revealed that upper respiratory tract symptoms,
hypertension, pulmonary basic diseases, high level of white blood cells,
lymphocyte counts, C-reactive protein, lower serum albumin, blood urea
nitrogen, were associated with mortality risk in COVID-19. Conclusion:
Patients with older age, comorbidities, lower lymphocyte counts in
hemogram and serum albumin, high c reactive protein level and renal
dysfunction may have higher risk to death. It warned us that more
attention should be given more attention on risk management in the
progression of COVID-19.